SCHEMBL2375985

SCHEMBL2375985

Cc1sc2nc(NCCO)nc(NCc3ccccn3)c2c1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KCNH2 Q12809 4/20 0.42
EGFR P00533 1/20 0.42
PDE10A Q9Y233 1/20 0.40
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
IGF1R P08069 2/20 0.39
FGFR1 P11362 1/20 0.39
KDR P35968 1/20 0.39
TNF P01375 1/20 0.39
MAPK1 P28482 1/20 0.39
NOD1 Q9Y239 1/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369432 0.87 GAA (0.36) MEN1KMT2ALMNAHTTMAPK1
SCHEMBL2368953 0.86 KCNH2 (0.48) MEN1KMT2AKCNH2LMNATSHR
SCHEMBL2368909 0.83 KCNA5 (0.44) MEN1KMT2AKCNH2PDE10AIGF1R
SCHEMBL2368717 0.82 MEN1 (0.45) MEN1KMT2AKCNH2EGFRLMNA
SCHEMBL2368823 0.82 KCNA5 (0.51) MEN1KMT2AKCNH2EGFRPDE10A
SCHEMBL2368294 0.78 CLK4 (0.47) MEN1KMT2AKCNH2LMNATSHR
SCHEMBL2369128 0.76 TNF (0.65) KCNH2IGF1RTNFMAPK1NOD1
SCHEMBL2368043 0.74 PRKCI (0.45) KCNH2LMNAFGFR1MAPK1MAPT
SCHEMBL3382594 0.74 KCNH2 (0.49) MEN1KMT2AKCNH2LMNATSHR
SCHEMBL2368804 0.73 TNF (0.55) KCNH2LMNAIGF1RFGFR1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MEN1 265/4885KMT2A 1857/4885KCNH2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.